Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An extension study to evaluate the persistence of the immune responses induced by GSK Biologicals Zoster Vaccine, GSK324332A, administered in healthy adult subjects aged 18-30 years and 50-70 years.

Trial Profile

An extension study to evaluate the persistence of the immune responses induced by GSK Biologicals Zoster Vaccine, GSK324332A, administered in healthy adult subjects aged 18-30 years and 50-70 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2019

At a glance

  • Drugs Varicella zoster virus glycoprotein vaccine (Primary) ; AS01B; Varicella zoster virus vaccine live
  • Indications Herpes zoster
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Apr 2019 Results published in the Vaccine
    • 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
    • 09 Sep 2008 Actual patient number (34) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top